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France; and 4Universite´ Paris-Sud, Orsay, FranceABSTRACT Smac-DIABLO in its mature form (20.8 kDa) binds to baculoviral IAP repeat (BIR) domains of inhibitor of
apoptosis proteins (IAPs) releasing their inhibitory effects on caspases, thus promoting cell death. Despite its apparent molec-
ular mass (~100 kDa), Smac-DIABLO was held to be a dimer in solution, simultaneously targeting two distinct BIR domains. We
report an extensive biophysical characterization of the protein alone and in complex with the X-linked IAP (XIAP)-BIR2-BIR3
domains. Our data show that Smac-DIABLO adopts a tetrameric assembly in solution and that the tetramer is able to bind
two BIR2-BIR3 pairs of domains. Our small-angle x-ray scattering-based tetrameric model of Smac-DIABLO/BIR2-BIR3 high-
lights some conformational freedom of the complex that may be related to optimization of IAPs binding.INTRODUCTIONThe 1.5 kb cDNA of second mitochondria-derived activator
of caspases/direct IAp binding with low pI (Smac-DIA-
BLO) encodes a 239 amino acid protein (27.1 kDa). The
first 55 amino acids are a mitochondrial targeting signal
peptide that is cleaved to generate mature Smac-DIABLO
(1). When released from mitochondria, Smac-DIABLO
acts as a natural antagonist of inhibitor of apoptosis proteins
(IAPs). Smac-DIABLO antagonistic activity is based on its
N-terminal tetrapeptide (AVPI) that binds baculoviral IAP
repeat (BIR) domains of IAPs, releasing their inhibitory ef-
fects on both initiator and effector caspases, thus promoting
cell death (2,3). Loss of regulation in apoptotic processes
is a known component of many pathologic states, such as
cancer and autoimmune diseases (4,5). In this respect,
Smac-DIABLO AVPI N-terminal tetrapeptide has been
extensively exploited to model Smac-mimetic compounds
as potential proapoptotic agents for cancer therapy (6).
Structural evidences (7,8) have shown that Smac-DIABLO
may act as a dimer, simultaneously targeting two distinct
BIR domains. Accordingly, to mimic the endogenous
protein action, several divalent Smac-mimetic compounds
(hosting two active functional groups) were synthesized
(9,10).
The first biophysical characterization of Smac-DIABLO
reported an apparent molecular mass, estimated through
gel filtration analysis, of ~100 kDa (1) that, considering
the molecular mass of the mature protein (20.8 kDa),
would suggest tetrameric/pentameric assembly. However,Submitted September 10, 2014, and accepted for publication November 26,
2014.
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0006-3495/15/02/0714/10 $2.00despite a thorough analysis of crystal packing aiming
at the identification of possible oligomeric species, the
authors of the first Smac-DIABLO crystal structure
did not report any plausible quaternary assembly state
beyond the dimer (7). The apparent disagreement between
crystallographic data and the gel filtration experiments
was attributed to the very elongated shape of the dimer,
which would yield a larger apparent molecular mass on a
globular protein scale.
In the framework of our long-term, multidisciplinary
characterization of IAPs, of their Smac-DIABLO natural
inhibitor, and of Smac-mimetic inhibitors, we undertook
a structural investigation of Smac-DIABLO bound to a
construct hosting two domains BIR2 and BIR3 of XIAP
(X-linked IAP (11)), its natural target protein. Because crys-
tallization of the Smac-DIABLO/BIR2BIR3 complex
proved problematic, we employed the small-angle x-ray
scattering (SAXS) approach to obtain information on such
assembly in solution. Our SAXS results on Smac-DIABLO
alone and in complex with XIAP-BIR2BIR3 (hereafter
designated by XIAP-BIR23 or BIR23 in short), reveal the
presence of a Smac-DIABLO tetramer in solution, a finding
confirmed by size-exclusion chromatography-static light
scattering (SEC-LS) measurements. Both observations
prompted us to pursue a new crystallographic investigation
of Smac-DIABLO quaternary assembly. Analysis of the
crystal packing interfaces in our structure, and in those
already available, shows the presence of an additional
dimer, besides that already described (7,8). One of the
Smac-DIABLO tetramers obtained by combining the two
dimeric interfaces yields a quaternary assembly in excellent
agreement with the SAXS experimental curve. Furthermore,
the SAXS data of the Smac-DIABLO/BIR23 complex fully
support the model whereby the identified tetramer wouldhttp://dx.doi.org/10.1016/j.bpj.2014.11.3471
TABLE 1 X-ray data-collection and refinement statistics for
Smac-DIABLO
Beam line and wavelength (A˚) ESRF ID 14-4 0.979
Space group P65
Unit-cell parameters (A˚) a ¼ b ¼ 91.0; c ¼ 113.8
Molecules in a.u. 2
Resolution (A˚) 45.5–1.8

Smac-DIABLO Tetrameric Assembly 715interact with two BIR23 monomers, with a stoichiometry of
one BIR domain per Smac-DIABLO chain.
Overall, our crystallographic and SAXS tetrameric
models of Smac-DIABLO, alone and in complex with
BIR23, shed some light on the structural basis of the protein
role as IAP inhibitor, and may support the design of a new
class of proapoptotic Smac-mimetic compounds.Mosaicity ( ) 0.4
Unique reflections 49,249 (7,211)a
Completeness (%) 99.6 (100.0)
Redundancy 7.5 (7.6)
Rmergeb (%) 5.6 (57.0)
Average I/s (I) 18.6 (3.2)
R factorc/Rfreed (%) 16.9/20.2
r.m.s. bonds (A˚) 0.012
r.m.s. angles () 1.34
Average protein B fac. (A˚2) A ¼ 40.2
B ¼ 38.7
Residues in most favored regions (%) 98.8
Residues in additionally allowed regions (%) 1.2
PDB-ID 4TX5MATERIALS AND METHODS
Cloning, expression, and purification of human
Smac-DIABLO
The plasmid coding for the mature protein form (184 amino acids) with
C-terminal His-tag was used to transform Escherichia coli strain
BL21(DE3). The 192-residue long recombinant protein was purified using
Ni-NTA (His-trap FF crude, GE-Healthcare), followed by gel filtration
(Superdex 200, GE-Healthcare). Smac-DIABLO was eluted in 20 mM
Tris/HCl pH 8.0, 250 mM NaCl, 10 mM DTT, and concentrated to 4 mg
ml1 using an Amicon Ultra Centrifugal Filter (10 kDa cutoff).
aValues in parentheses are for the highest resolution shell: (1.9–1.8).
bRmerge ¼ S jI - (I)j / S I  100, where I is intensity of a reflection and (I)
is its average intensity.
cRfactor ¼ S jFo - Fcj / S jFoj  100.
dRfree is calculated on 5% randomly selected reflections, for cross-validation.Cloning, expression, and purification of human
XIAP-BIR23 domain
The sequence coding for region 141-356 of XIAP (BIR2 and BIR3
domains) was cloned in pET28(b) (Novagen), in NheI-BamHI sites. The
plasmid was used to transform E. coli strain BL21(DE3), and the expressed
protein was purified as previously described (12). The protein was stored in
20 mM Tris/HCl pH 7.5, 200 mM NaCl, and 10 mM DTT.Smac-DIABLO crystallization and crystal
structure analysis
Sitting drop crystallization experiments were prepared using an Oryx-8
robot (Douglas Instruments, East Garston, UK), from a 2:1 mixture of
Smac-DIABLO (4 mg ml1) and the precipitant solutions, to a final droplet
volume of 0.3 ml. After 4 days of vapor diffusion at 20C, prismatic crystals
were obtained in 30% 2-methyl-2,4-pentanediol (MPD), 0.1 M sodium ac-
etate, pH 4.6 and 0.02 M calcium chloride. Before flash-cooling in liquid
nitrogen, the Smac-DIABLO crystals were transferred into a cryoprotectant
solution (35% MPD, 0.1 M sodium acetate, pH 4.6, 0.02 M calcium chlo-
ride, and 25% glycerol). The crystal used for data collection diffracted to a
maximum resolution of 1.8 A˚, using synchrotron radiation on beamline ID
14-4, at the European Synchrotron Radiation Facility (ESRF-Grenoble,
France). The diffraction data were processed with MOSFLM (13), and in-
tensities were merged using SCALA (14). Smac-DIABLO crystals belong
to the hexagonal P65 space group with unit cell parameters a ¼ b¼ 91.0 A˚,
c ¼ 113.8 A˚, with two protein molecules in the crystal asymmetric unit
(a.u.; VM ¼ 2.2 A˚3 Da1, 62% solvent content). The crystal structure was
solved by molecular replacement (MOLREP (15)), using as a search model
the available Smac-DIABLO structure (7); Protein Data Bank (PDB) ID:
1FEW). The two independent molecules in the a.u. were subjected to
rigid-body refinement, and restrained refined using REFMAC5 (16). A
random set comprising 5% of the data was omitted from refinement for
R-free calculation. Manual rebuilding (COOT (17)) and additional refine-
ment using BUSTER (18) were subsequently performed.
The refined Smac-DIABLO model displays almost the entire amino acid
chain: the first 12–13 N-terminal residues of both chains A and B, and the
last 5 C-terminal residues in chain B are disordered. Data collection and
refinement statistics are summarized in Table 1. Atomic coordinates and
structure factors have been deposited in the PDB (19) with accession
code 4TX5.SAXS
X-ray scattering data of Smac-DIABLO alone or complexed to XIAP-
BIR23 were collected at the beamline SWING of the SOLEIL synchrotron
(Gif-sur-Yvette, France). The data were recorded using a charge-coupled
device-based detector (AVIEX) with a sample-detector distance of 2.07
m, covering the momentum transfer range 0.0064 A˚1 < q < 0.40 A˚1
(q ¼ 4p sinq/l, where 2q is the scattering angle, and l ¼ 1.033 A˚ the wave-
length of the x-rays). Measurements were performed using the size exclu-
sion HPLC instrument (Agilent) online with the SAXS measuring cell, a
1.5 mm diameter quartz capillary contained in an evacuated vessel (20).
Smac-DIABLO alone or in complex with XIAP-BIR23 was studied at
10C in Tris/HCl buffer 20 mM pH 7.5, NaCl 200 mM, and 10 mM
DTT. Briefly, 35 ml of a 5 mg ml1 sample solution were loaded onto the
equilibrated column. Scattering of the elution buffer before void volume
was recorded and used as buffer scattering to be further subtracted from
all protein patterns. 2 s successive frames were recorded separated by a
0.5 s interval because the elution flow of 0.15 ml/min ensured that no pro-
tein was irradiated for >0.4 s.
Primary data reduction was performed using the SWING in-house soft-
ware Foxtrot. Data were subsequently processed using the program package
PRIMUS (21). The forward scattering I(0) and the radius of gyration (Rg)
were evaluated using the Guinier approximation (22). Frames over the
elution peak were analyzed individually before averaging the appropriate
subset that yielded identical Rg and I(0)/c values. The corresponding con-
centration was determined using the ultraviolet absorbance detector from
the HPLC system and the values of the protein absorbance at 280 nm
ε
280¼ 22,920 M1cm1 for Smac-DIABLO and ε280¼ 54,890 M1cm1
for XIAP-BIR23. The appropriate linear combination of these values
was used for the complex of Smac-DIABLO with BIR23. The distance
distribution function p(r) was determined using the indirect Fourier trans-
form method as implemented in the program GNOM (23). The molecular
masses of the solutes were evaluated by comparison of the forward
scattering with that of water recorded in the same capillary using the value
of 0.001647 cm1 for the theoretical scattering intensity of water at 10C
(http://physchem.kfunigraz.ac.at/sm/). An alternative estimate of theBiophysical Journal 108(3) 714–723
716 Mastrangelo et al.molecular mass was obtained using the SAXS MoW program (available at
the URL http://www.if.sc.usp.br/~saxs/) that is based on the determination
of the Porod volume (24), which is independent of the sample concentra-
tion. Finally, the molecular mass was also determined from the SAXS
data using the power law relating the ratio QR ¼ Vc2/Rg and the mass as
reported in (25).FIGURE 1 Smac-DIABLO dimeric interfaces d1 (left) and d2 (right) as
observed in the three crystal structures. Left: dimerization through d1 inter-
face creates an arch-shaped molecule with the N-termini at the top of the
arch and the C-termini at the two ends of the arch. Right: dimerization
through d2 interface.Static light scattering
We performed size exclusion chromatography-static light scattering
(SEC-LS) measurements on Smac-DIABLO alone (starting concentration
115 mM) and on its complex with the XIAP-BIR23 construct (starting
concentrations 92 mM and 50 mM, respectively) using Viscotek SEC – Tetra
Detection Array (TDA) instrument (Malvern Instruments). Eluting solu-
tions were monitored using: 1) ultraviolet-visible spectrophotometer; 2)
7 low-angle light scattering; 3) 90 right-angle light scattering; and 4)
differential refractometer. Data acquisition and analysis were conducted
using the OmniSEC software (Malvern Viscotek). Typically, 150 ml of
sample in 20 mM Tris/HCl buffer pH 7.5, 200 mM NaCl, 10 mM freshly
added DTT were loaded onto a Superdex 200 column (GE Healthcare)
equilibrated in the same buffer, and eluted at a flow rate of 0.5 ml min1.
Bovine serum albumin dissolved in the same buffer was used as a reference
protein of known molecular mass, concentration, and refractive index incre-
ment (dn/dc ¼ 0.185 ml g1) that allowed us to determine all instrument-
response factors of the detectors.Dynamic light scattering (DLS)
The purified Smac-DIABLO protein was centrifuged at 13,000  g for
10 min before DLS analysis; all measurements were carried out at 4 and
20C in a DynaPro instrument (Protein Solutions, Charlottesville, VA).
DLS measures (c ¼ 69 mM) show a hydrodynamic radius RH y 5.6 5
0.1 nm (polydisp. ¼ 175 4%).Modeling the quaternary assembly of
Smac-DIABLO
The PISA software, an interactive tool for the exploration of macromolec-
ular interfaces (26), available at the EMBL-EBI website (http://www.ebi.ac.
uk/pdbe/pisa/), was run on the crystallographic coordinates of the two
Smac-DIABLO structures already reported (PDB IDs 1FEW (7) and
1G73 (8)) and on the Smac-DIABLO structure presented here. PISA iden-
tified two distinct plausible dimeric assemblies for all three structures:
dimer 1 (d1) and dimer 2 (d2) (Fig. 1). d1, already described in (7), has
an extended arch-like shape with buried area of ~2000 A˚2. d2 is more
compact, with Smac-DIABLO monomers mainly interacting through the
antiparallel a3 helices (buried area 2210 A˚2, Fig. 1). Based on the identified
interfaces two different tetramers can be built by combining two d1 or d2
dimers around the other dimeric interface (d2 or d1, respectively).
The few missing residues at the chain termini were modeled by super-
position or added manually in random orientation (such as the 8 C-terminal
residues of the His-tag (LEH6)) using PyMol (http://www.pymol.org) or
COOT (17). The scattering patterns of all high-resolution models were
computed using the program CRYSOL (27). The tetramer that displays
the best agreement with the SAXS data is that obtained assembling two
d1 dimers through the d2 interface, starting from 1FEW PDB coordinates.Modeling the Smac-DIABLO/BIR23 complex
By superimposition of the Smac-DIABLO/XIAP-BIR3 complex (PDB ID:
1G73 (8),) over each Smac-DIABLO chain of our best tetramer (see above),
we obtained a complex comprising four Smac-DIABLO chains and four
BIR3 domains, each interacting with the N-terminal AVPI tetrapeptide ofBiophysical Journal 108(3) 714–723a Smac-DIABLO chain. Two BIR3 domains were then substituted with a
BIR2 domain (using the coordinates of the E chain in the PDB ID 1I3O
(28)). Our construct used for SAXS measurements comprises XIAP-
BIR23 residues Leu-141 through Thr-355, with an extra N-terminal methi-
onine originating from the vector and the C-terminal His-tag (LEH6); the
model was modified accordingly. The assembled complex, in which 2
BIR2 and 2 BIR3 domains interact with the Smac-DIABLO tetramer,
was then our starting model for structural refinement against SAXS data
using the program CORAL (29). The program was used to perform a
rigid-body search of the position of the four BIR domains with respect to
the rest of the complex, while treating the two linkers between BIR2 and
BIR3 (23 residue-long) and the four linkers between the AVPI tetrapeptides
and the structured part of each SD chain (starting from amino-acid residue
12) as chains of dummy residues (DR). The core of Smac-DIABLO
tetramer was kept fixed. The first N-terminal tetrapeptide AVPI of each
Smac-DIABLO chain was included in the corresponding BIR domain
and moving alongside under distance restraint of 8 A˚ between the 4th
amino-acid (Ile) and the first dummy residue in the flexible linker (5th res-
idue of each SD chain) to allow for subsequent restoration of chain connec-
tivity. A selected refined model was used as a starting structure for a
molecular dynamics (MD) simulation run as explained below.MD simulations of the Smac-DIABLO tetramer
The MD simulations were performed using the program NAMD2 (30).
Briefly, we started from the Smac-DIABLO tetramer assembly best fitting
the SAXS data as described previously (two d1 dimers assembled through
the d2 interface) based on the 1FEW PDB coordinates. Using the program
psfgen (part of the namd2 package (30)) H-atoms were added and partial
charges assigned to every atom in the structure. A box was then built around
the protein (99.9  94.3  172.9 A˚3) and filled with 47,302 water
molecules. The charge equilibration of the system was performed adding
NaCl 0.2 M (177 Cl and 229 Naþ ions, using the VMD package; http://
www.ks.uiuc.edu/Research/vmd/). Initially, harmonic constraints to fix
protein atom positions during energy minimization of the solvent were
applied for 0.5 ns, before equilibrating the system at 310 K for an additional
0.5 ns. The simulation was then started and lasted ~2.26 ns, with 2 fs time
steps. During the simulation periodic boundary conditions in NPT
ensemble, with Langevin temperature control (T ¼ 300 K) and Langevin
Smac-DIABLO Tetrameric Assembly 717piston Nose-Hoover method (31), were used to maintain constant tempera-
ture and pressure, respectively. Van der Waals interactions were handled
with a cutoff of 12 A˚, and switched off using a smoothing function beyond
10 A˚. The electrostatic interactions were treated with the particle mesh
Ewald method (32), using a grid of 200 points along each dimension of
the simulation box.MD simulations of the Smac-DIABLO/BIR23
complex
The simulation started from the coordinates of one rigid body model of
Smac-DIABLO/BIR23 complex obtained with CORAL, followed by DR
replacement with an all atom description using COOT (17). The model
was inserted into a box of 136.1  146.4  156.7 A˚3 filled with 91,515
water molecules and equilibrated adding NaCl 0.2 M (346 Cl and 413
Naþ ions). After minimization and equilibration, the MD simulation
was run for 20 ns under the same conditions already described for Smac-
DIABLO alone.RESULTS
Smac-DIABLO crystal structure
Smac-DIABLO crystallized in the hexagonal space group
P65, with two molecules per asymmetric unit. The protein
structure was solved by molecular replacement using as
search model the PDB coordinates 1FEW (space group
P6122, 1 molecule per asymmetric unit) (7). The overall dif-
ferences in the crystal packing of the two structures are
highlighted in Fig. S1 in the Supporting Material. The final
crystallographic R-factor/R-free values are 16.9/20.2%, for
data in the 45.5–1.8 A˚ resolution range (Table 1). Our final
atomic model contains residues 15–187 (three residues of
the C-terminal tag are visible in the electron density map)
in chain A, and 13–179 in chain B. No electron density is
seen for the N-terminal segment, confirming that this pro-
tein region is highly mobile in the absence of interaction
with BIR domains.
The Smac-DIABLO monomer is an elongated three-helix
bundle (a1–3) with moderate curvature as already reported
(7,8) (Fig. 1). Structural superposition of the two a.u. inde-
pendent protein Ca backbones yields a root mean-square
deviation (r.m.s.d.) of 0.87 A˚ (based on 164 amino acid
pairs) the main differences arising from slight axial
misalignment of the two longer C-terminal helices (63
amino acid long).
Interfaces in crystal structures
The two Smac-DIABLO molecules in the a.u. of our crystal
structure provide a dimeric assembly through a hydrophobic
interface formed by the N-terminal half of helix a1 and
the C-terminal third of helix a2 (roughly from Leu-98 to
Thr-119), resulting in a buried surface area of 2060 A˚2
(analyzed with the program PISA). Dimerization through
this interface creates an elongated arch-shaped molecule,
similar to those already reported (PDB ID: 1FEW (7,8);
PDB ID: 1G73) (Fig. 1, d1). In our dimer, the angle formedby the two legs of the arch is ~130, larger than that reported
by Chai et al. (~100; buried area 2000 A˚2; Fig. 1) but
smaller with respect to the C-ter truncated construct of
Smac-DIABLO in complex with XIAP-BIR3 (~140;
buried area 1950 A˚2 (8); PDB ID: 1G73) (Fig. 1). In all three
crystals, the program PISA identifies an additional interac-
tion surface involving helices a3 of two symmetry related
molecules in an antiparallel arrangement (buried areas of
2200, 2490, and 2210 A˚2, in our structure 4TX5, 1G73,
and 1FEW, respectively) (Fig. 1, d2). Therefore, in all the
high-resolution structures available, Smac-DIABLO ex-
hibits two kinds of dimeric interfaces: a tight arch-shaped
dimer (d1) and the a1–a3 helical bundle (d2) (Fig. 1).SAXS study of Smac-DIABLO alone and in
complex with XIAP-BIR23
Samples of Smac-DIABLO and of the Smac-DIABLO/
BIR23 complex were loaded onto the SE-HPLC column
and series of SAXS patterns were recorded during elution
of the proteins (see Materials and Methods). The two result-
ing patterns are shown in Fig. 2 A, the corresponding Guin-
ier plots are shown in the inset to A and the two distance
distribution functions p(r) in B, whereas the Rg, MM, and
Dmax values are summarized in Table 2.
The large Rg value for Smac-DIABLO (~45 A˚) is not un-
expected (1) but theMMestimate from I(0)/c data (76.5 kDa)
is closer to that of a tetramer instead of the proposed
dimer (43.7 kDa (7)). This is confirmed by the estimate of
90 kDa provided by both the SAXS MoW program and the
power law of QR. In addition, the molecular mass measured
for the Smac-DIABLO/BIR23 complex (134 kDa from the
I(0)/c value, 154 kDa from SAXSMoWandQR) corresponds
to that of a Smac-DIABLO tetramer bound to two molecules
of XIAP-BIR23 (139.6 kDa).SEC-LS of Smac-DIABLO alone and in complex
with XIAP-BIR23
To confirm the tetrameric assembly of Smac-DIABLO, we
performed a static light scattering experiment on the protein
alone and on its complex with XIAP-BIR23. The samples
were eluted from a SEC column while monitoring the pro-
tein concentration through refractometry measurements.
The molecular mass values obtained through the protein
refractive index peak are shown in Fig. 3, A and B. The
values confirm that Smac-DIABLO is a tetramer able to
bind two molecules of XIAP-BIR23. It is worth adding
that we never observed a peak of dimer in SEC-LS measure-
ments or in SEC-SAXS measurements.DLS of Smac-DIABLO
DLS measurements performed on various Smac-DIABLO
samples (c ¼ 69 mM), consistently showed a hydrodynamicBiophysical Journal 108(3) 714–723
FIGURE 2 SAXS patterns of Smac-DIABLO
and of the Smac-DIABLO/XIAP-BIR23 complex.
The scattering patterns (A) and distance distribu-
tion functions p(r) (B) of Smac-DIABLO solutions
in the absence/presence of XIAP-BIR23 are shown
in green and red, respectively. The inset in (A)
shows the two corresponding Guinier plots.
718 Mastrangelo et al.radius of the order of 5 nm compatible with the diffusion of
a very elongated tetramer, or of a more compact higher order
oligomer, therefore excluding the presence of a dimer in
solution.Smac-DIABLO modeling using SAXS and crystal
structures
Starting from our SAXS data, we decided to model
possible Smac-DIABLO assemblies in solution using the
available crystal structures (33). The scattering patterns
of various protein assemblies were computed using the pro-
gram CRYSOL (27) and compared to the experimental





Instrument beamline SWING (synchrotron SOLEIL)
Detector charge-coupled device-based AVIEX
Beam geometry 0.8  0.15 mm
Wavelength [A˚] 1.0
q-range [A˚1] 0.0064 < q < 0.40
Exposure time [s] 2
Temperature [K] 283
Structural parameters
I(0) Guinier [cm1] 0.0416 0.0556
Rg Guinier [A˚] 44.85 0.3 48.55 0.3
I(0) p(r) [cm1] 0.0420 0.0556
Rg p(r) [A˚] 45.85 0.2 48.95 0.2
DMax [A˚] 160 180
Molecular mass determination




MMI(0)/c [kDa] 76.5 134.3
MMSAXS MoW [kDa] 90 154
MMSAXS QR [kDa] 90 154
Biophysical Journal 108(3) 714–723of both d1 and d2 dimers that we could detect in the
1FEW coordinates set (Fig. 1). Both exhibited very large
deviations from the experimental data, indicating that di-
mers are not present in solution (Fig. S2). We therefore
built two distinct tetramers based on the d1 and d2
observed dimeric interfaces (Fig. 1): two d2 dimers associ-
ated through the d1 interface d24
d1
d2 and, reciprocally,
two d1 dimers associated through the d2 interface
d14
d2
d1. Although the scattering pattern of the former
tetramer is significantly different from our experimental
data (dark green curve in Fig. 4), the d14
d2
d1 tetramer
yields a good agreement with the experimental data with
a c value of 3.3 (cyan curve in Fig. 4).
Subsequently, using the analogous d14
d2
d1 tetramer ex-
tracted from our crystal structure (4TX5) we obtained a
different scattering pattern, mainly due to the structural
differences observed in the d2 type dimers (blue curve in
Fig. 4 and Fig. 1, d2).
Considering the structural variations displayed by
Smac-DIABLO in the crystals, notably at the level of
the C-terminal a3 helix curvature, we speculated that
the protein molecule is likely to explore in solution a
rather large conformational space through the intrinsic
flexibility of each chain. To test this hypothesis, we
performed a short MD simulation on the 1FEW d14
d2
d1
tetramer and calculated the scattering patterns of hundreds
of snapshots along the trajectory. A few conformations
were found to yield an improved agreement with the
experimental data, the best one yielding a c value of
1.85 (red curve in Fig. 4), showing that the molecule flex-
ibility, mainly through the long C-terminal a3 helix, was
large enough for the tetramer to explore significantly
different conformations (for instance Ca181 of chain D
displacement was ~10 A˚ from its original position, see
Fig. S3). Because what is observed in solution is a
combination of a very large number of conformations,
we endeavored to fit the experimental data by an ensemble
of conformations using EOM (34) and the set of MD
FIGURE 3 SEC-LS measurements of Smac-
DIABLO (A) and of the Smac-DIABLO/XIAP-
BIR23 complex (B). Molecular mass (red line,
right-hand side scale) along the refractive index
peak (blue line). The second peak seen in (B)
corresponds to the excess of XIAP-BIR23 in the
mixture loaded on the column.
Smac-DIABLO Tetrameric Assembly 719snapshots. The resulting ensembles either yielded worse
fits, or contained (if authorized) a majority of the best
fitting conformation presented previously. Our short MD
simulation offered only a glimpse at the conformational
space available to the protein. However, our aim hereFIGURE 4 Scattering patterns of models of Smac-DIABLO tetramers. (A) Ex
the tetramer derived from our crystal form (PDB ID: 4TX5) d14
d2
d1 (blue); calcu
from PDB ID: 1FEW; calculated pattern of the best snapshot along the MD traj
Reduced residuals corresponding to the last two curves in (A) (same color cod
curves with a label framed using the same color code.was not to identify the best ensemble fitting our data
(there are innumerable such ensembles); rather we aimed
to show that the intrinsic dynamics of the tetramer allow it
to reach conformations with detectably different SAXS
patterns.perimental scattering curve of Smac-DIABLO (black); calculated pattern of
lated pattern of tetramers d24
d1
d2 (dark green), and d14
d2
d1 (cyan) derived
ectory starting from d14
d2
d1 tetramer 1FEW (see text for details) (red). (B)
e). Right-hand side column: models corresponding to the three calculated
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SAXS and crystal structures
We combined the best tetrameric assembly of Smac-
DIABLO (identified as described previously), together
with the structural information provided by the crystal struc-
ture of Smac-DIABLO/BIR3 complex (PDB ID: 1G73) to
create an assembly of 4 Smac-DIABLO molecules and 2
XIAP-BIR23 constructs, each BIR domain interacting
with one Smac-DIABLO chain as shown in 1G73 (see
Materials and Methods for details). The scattering curve
calculated from such a model exhibited major differences
relative to the experimental scattering pattern (Fig. 5, blue
curve), with a c value of 11.
In particular, the well-resolved minimum and maximum
observed on our model curve in the q-range [0.12–
0.18 A˚1], a feature much sharper than the experimental
shoulder around 0.15 A˚1, suggest that the model used is
too symmetric as compared to the real complex in solution.
Because we are studying a noncovalent complex, the pres-
ence of a mixture of complex and isolated partners would
certainly cause a marked blurring in the scattering curve fea-
tures. Smac-DIABLO exhibits very high affinity for the
XIAP-BIR23 construct, with subnanomolar dissociation
constant (35), whereas our sample concentration in the
x-ray beam is of the order of 15 mM for the Smac-DIABLO
chain. Although we can thus exclude the presence of
unbound BIR23, we cannot rule out the existence of hetero-
geneity within the Smac-DIABLO/BIR23 complex, arising
from equilibria between bound/unbound states of each BIR
domain. The affinity of individual BIR domains within the
BIR23 constructs is unknown, but can be expected to beBiophysical Journal 108(3) 714–723intermediate between that of isolated BIR domains—Kd
values of ~4 mM for BIR3 and 1 mM for BIR2—and the
0.3 nM reported for BIR23 (35). If we assume a common
Kd value of ~20 nM for each BIR domain, a simple calcula-
tion yields an estimate of>95% BIR domains bound to their
Smac-DIABLO binding site, thus suggesting that practically
all BIR domains are bound to Smac-DIABLO in our sample.
Examination of the crystal structure of the complex be-
tween Smac-DIABLO and BIR3 (PDB ID: 1G73) shows
that although the N-terminal tetrapeptide AVPI exhibits an
extended set of interactions with BIR3 that explains the
high affinity, no relevant contacts affect the downstream res-
idues (5–11) and the BIR3 domain. Therefore, we reasoned
that, within the tetrameric complex, BIR2 and BIR3 do-
mains could be relatively mobile because, 1) they are con-
nected to each other through a flexible 23 residue-long
linker and 2) each BIR domain is linked (through AVPI)
to the tetrameric core of Smac-DIABLO by a seven-resi-
due-long flexible sequence. We made several attempts to
model the BIR23 domain conformational flexibility using
the program CORAL (29). Such analysis yielded a good
fit to the data (c ¼ ~1.6) that worsened upon dummy
residue replacement by proper residues and connectivity
restoration (c ¼ ~3) (green curve in Fig. 5), suggesting
that the limited mobility of the bound BIR domains was
enough to produce models roughly compatible with our so-
lution data. Our structural model does not postulate a unique
conformation of the complex; rather, it proposes that,
beyond the intrinsic flexibility of the Smac-DIABLO
tetramer, BIR23 domains explore a wide conformational
space through the mobility of the two flexible linkers: 1)FIGURE 5 Modeling the Smac-DIABLO/XIAP-
BIR23 complex. (A) Experimental scattering
pattern of the complex (black); calculated scat-
tering pattern of the complex obtained by
combining the crystal tetramer of Smac/DIABLO
with BIR3 (PDB ID: 1G73) (blue); calculated scat-
tering pattern of the CORAL model after dummy
residue replacement and connectivity restoration
(green); NNLS fit obtained using the 625 snapshots
along the MD trajectory (red). (B) Reduced resid-
uals corresponding to the last two curves in (A)
(same color code). Right-hand side column:
models corresponding to the three calculated
curves framed using the same color code.
Smac-DIABLO Tetrameric Assembly 721between BIR2 and BIR3 domains (23 amino acids) and 2)
between the AVPI tetrapeptide and the helical core of
Smac-DIABLO (7 amino acids).
To further test this hypothesis we performed a MD simu-
lation starting from one of our CORAL models, after
dummy residue replacement and connectivity restoration.
We extracted 625 frames from the MD trajectory (total
simulation time 20 ns, Dt ¼ 32 ps), calculated their scat-
tering patterns and from a nonnegative linear least-square
analysis using the US-SOMO software (36) obtained a
good fit to our data (c ¼ 1.76) (red curves in Fig. 5) using
a subset of three conformational states with fractional con-
centrations ranging from 10% to 53%. After superimposi-
tion, the three models exhibit Ca r.m.s.d. of 6.35 A˚,
8.05 A˚, and 5.3 A˚. In conclusion, we propose a model for
the Smac-DIABLO/BIR23 complex in which the BIR2
and BIR3 domains exhibit restricted mobility around the
tetrameric core of Smac-DIABLO, without ruling out the
existence of a minor fraction of structures exhibiting one
unbound BIR domain.DISCUSSION
Smac-DIABLO was reported to behave as an oligomer in
solution, with an apparent molecular mass of 100 kDa (1).
Because of its elongated shape, Smac-DIABLO is expected
to exhibit a much larger radius of hydration in solution than
a globular protein with the same molecular mass. After an
extensive study of crystal interfaces and a major effort of
mutants production to test the relevance of various contacts,
Chai et al. concluded that the arch-like extended dimer was
the biologically active oligomer stable in solution (7).
On the other hand, the structural analysis reported here, us-
ing the program PISA (26), shows that the three available
crystal structures share two, qualitatively similar, interfaces
(d1 and d2, Fig. 1). Here, combining SEC-SAXS and SEC-
LS measurements we show that Smac-DIABLO is present in
solution as a tetramer. Moreover, a plausible high-resolution
tetrameric model that fits well the SAXS data can be
recognized as the result of dimers d1 (7) assembled through
the crystallographic interface d2 observed in 1FEW
(d14
d2
d1) (Fig. S4). Relaxing the modeled tetramer with
MD simulation we obtained an even better fit to the SAXS
data, suggesting that Smac-DIABLO behaves in solution
like an ensemble of flexible tetramers mostly through
bending of their long C-terminal helix.
Crystal contact analysis aims at discriminating stable
intermolecular interfaces that could be maintained in dilute
solution from those that are the result of the very specific
crystallization conditions. This analysis is very often vali-
dated by mutation analysis of the investigated interaction,
but this is not always unambiguous as illustrated by this
study. Another case is that of survivin, a protein from the
IAP family for which two different dimers were observed
in different crystal forms (37,38), and for which mutationanalysis remained inconclusive (39). The case was solved
several years later by an NMR study (40). We also wish to
underline that the case of Smac-DIABLO is somewhat un-
usual in that the originally identified association interface
(d1) is correct, but a second one (d2) was overlooked, so
that the initially proposed biological assembly was one-
half of the newly proposed functional assembly.
Why was the d2 interface considered as a strict crystal
contact not to be observed in solution? It certainly did not
go unnoticed by the authors of the crystal structure: they
produced six mutations within this interface but reported
no change in the oligomeric state of the molecule. We can
only surmise that the interface is stable enough to survive
each of these mutations. We also believe that the changes
in the size exclusion chromatography elution profile
observed for several mutants within the d1 interface were
associated not with a dimer to monomer transition but
with a tetramer to (compact) dimer transition. Actually,
using the US-SOMO program (36) we calculated the Stokes
radius for all four species (monomer, compact, and extended
dimer and tetramer) and obtained comparable differences
for both transitions.
Starting from the Smac-DIABLO tetrameric structure we
modeled a Smac-DIABLO/XIAP-BIR23 complex, with 4:2
stoichiometry, which fits well the SAXS data. Moreover, we
demonstrated that the four BIR domains in the complex
exhibit a moderate level of mobility around the tetrameric
core of Smac-DIABLO, resulting from the degrees of
freedom of the BIR2-BIR3 linker segment (23 amino acids)
and the Smac-DIABLO 5-11 N-terminal portion.
The tetrameric form of Smac-DIABLO could suggest
the rational design of tetravalent IAP inhibitors, mimicking
the four AVPI tetrapeptides in the complex. These may yield
even more potent drugs antagonizing IAPs but at the price
of a major increase in complexity if one considers the phar-
macochemical features required to turn an inhibitor into an
effective drug.
Smac-DIABLO fulfils its biological role of regulation of
apoptosis by interacting with inhibitors of apoptosis,
thereby allowing caspases activation. Accordingly, Smac-
DIABLO presents three intrinsic molecular properties that
could be instrumental in this regard. 1) It is a very acidic
protein (pI ¼ 4.8) with a net negative charge of ~13 for
each chain at close to neutral pH; 2) it forms tetramers in
solution; and 3) it exhibits significant flexibility both in
the long C-terminal helix but also at the N-terminus bearing
the AVPI tetrapeptide. The initial steps of interaction with
its IAP partners could be facilitated through long range
electrostatic interactions due to the net negative charge of
the tetramer exceeding 50. After such initial unspecific
attraction, the BIR domains would bind to Smac-DIABLO
through the highly specific AVPI tetrapeptide. Huang et al.
(35) showed that both BIR2 and BIR3 were required for
Smac-DIABLO to relieve the XIAP-mediated caspase inhi-
bition, showing enhanced affinity for the BIR23 constructBiophysical Journal 108(3) 714–723
722 Mastrangelo et al.with respect to the isolated domains. Furthermore, XIAP has
been reported to oligomerize probably through its RING
domain (41), and Gao et al. (42) showed that full-length
XIAP forms trimers in solution. It thus appears that the
affinity between Smac-DIABLO and XIAP depends on a
complex set of interactions that can provide not only the
extremely tight global binding but also fine-tuning through
interaction with other molecules and, possibly, modulation
of the oligomeric state of XIAP. Finally, the observed
conformational flexibility of Smac-DIABLO is most likely
to play a key role in its ability to bind various IAP partners,
as different as XIAP and survivin, but all major actors in the
regulation of apoptosis.SUPPORTING MATERIAL
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